Loxitane: Basic information

Basic information

Antipsychotics (antipsychotic), almost does not cause extrapyramidal disorders, increases the effects of hypnotic and analgesic drugs.
Pharmacologically, loxapine is an antipsychotic for which the exact mode of action has not been established. However, changes in the level of excitability of subcortical inhibitory areas have been observed in several animal species in association with such manifestations of tranquilization as calming effects and suppression of aggressive behavior.
In normal human volunteers, signs of sedation were seen within 20 to 30 minutes after administration, were most pronounced within one and one-half to three hours, and lasted through 12 hours. Similar timing of primary pharmacologic effects was seen in animals.

Loxitane

Loxitane

Product form:

25 mg tablets; Bank (Bank) 50 dark glass, paper cartons 1.
100 mg tablets; Bank (jar) dark glass 50, the paper cartons 1.
100 mg tablets; Bank (jar) polymer 50, the paper cartons 1.
25 mg tablets; Bank (jar) polymer 50, the paper cartons 1.
100 mg tablets; contour cell package 10 pack cardboard 5.
25 mg tablets; contour cell package 10 pack cardboard 5.

Metabolism and Excretion

Absorption of Loxitane following oral or parenteral administration is virtually complete. The drug is removed rapidly from the plasma and distributed in tissues. Animal studies suggest an initial preferential distribution in lungs, brain, spleen, heart, and kidney. Loxapine is metabolized extensively and is excreted mainly in the first 24 hours. Metabolites are excreted in the urine in the form of conjugates and in the feces unconjugated.

Indications and Usage

Loxitane is indicated for the treatment of schizophrenia. The efficacy of Loxitane in schizophrenia was established in clinical studies which enrolled newly hospitalized and chronically hospitalized acutely ill schizophrenic patients as subjects.

Contraindications

Hypersensitivity, granulocytopenia and agranulocytosis in history (with the exception of granulocytopenia or agranulocytosis as a result of previously used chemotherapy); impaired bone marrow function, myasthenia gravis, coma, toxic psychosis (including alcohol), pregnancy, lactation, children’s age (up to 5 years).
Caution: Acute decompensated cardiovascular disease, severe liver and / or kidney failure, angle-closure glaucoma, prostatic hyperplasia, intestinal, epilepsy, intercurrent illness with fever syndrome.
Loxitane is contraindicated in comatose or severe drug-induced depressed states (alcohol, barbiturates, narcotics, etc.).
Loxitane is contraindicated in individuals with known hypersensitivity to dibenzoxazepines.

Warnings

Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Precautions

Leukopenia, Neutropenia and Agranulocytosis

Information for Patients

Overdose

Symptoms: stupor, drowsiness, soporous condition, respiratory depression, coma, delirious disorders, the development of large seizures, anxiety, agitation, lability of fever, tachycardia, decreased blood pressure, heart rhythm disturbances, collapse, atonic bowel.
Treatment: gastric lavage with the appointment of adsorbents, maintaining respiratory function and cardiovascular system, control electrolyte balance and CBS; symptomatic treatment. For 4 days after the disappearance of the patients symptoms of poisoning establish observation because of possible late complications. Peritoneal dialysis or hemodialysis ineffective.
Given the likelihood that some patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.

Loxitane: Drug Interactions

There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazapam.
The risk of using loxapine in combination with CNS-active drugs has not been systematically evaluated. Therefore, caution is advised if the concomitant administration of loxapine and CNS-active drugs is required.

Loxitane: Side effects

CNS: dizziness, drowsiness, headache, fever of central origin, fainting, agitation, akathisia, confusion; rarely — extrapyramidal disorder (akinesia or hypokinesia, muscle rigidity, tremor), insomnia, sleep disturbances, depression, neuroleptic malignant syndrome (seizures, difficulty breathing or tachypnea, tachycardia or arrhythmia, fever, unstable blood pressure, sweating, urinary incontinence, severe muscle stiffness, pale skin, excessive tiredness or weakness), seizures, tardive dyskinesia. From the urogenital and urinary system: urinary retention, reduced potency. On the part of metabolism: increased body mass. From the musculoskeletal system: myasthenia gravis. From the digestive system: salivation, nausea, vomiting, heartburn, dry mouth. From the side of hematopoiesis: granulocytopenia, up to agranulocytosis (first signs of agranulocytosis may be flu-like symptoms: chills, fever, sore throat, inflammation of the gums and oral mucosa; languidly healing wounds, abrasions, exacerbation of chronic or latent foci of infection — tonsillitis, abscess, pyoderma), leukopenia, thrombocytopenia. From the senses: ccomodation. From the CCC: lowering blood pressure (including orthostatic hypotension), rarely — increased blood pressure, tachycardia, flattening of the T wave on the ECG. Other: increased sweating.